The following is a summary of “Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and ...

Type 1 diabetes is an autoimmune condition associated with genetics and may develop suddenly. Type 2 diabetes often develops over time, with obesity and a lack of exercise as the main risk factors.

Manufactured by Novo Nordisk, semaglutide is the newest in a family of glucagon-like peptide-1 (GLP-1) receptor agonists used most commonly to treat type II diabetes. To date, the results of ...

Use of GLP-1 RAs was associated with lower incidence of death-censored graft loss and lower mortality among kidney transplant recipients with diabetes. HealthDay News — Glucagon-like peptide-1 ...

New solution leverages Quantum Health’s clinical expertise, health coaching and holistic care coordination combined with Vida Health’s evidence-based prescribing to optimize GLP-1 utilization ...

All patients remained adherent to the GLP-1 medication through 8 months. "I believe combining the Allurion Balloon with low-dose GLP-1 therapy has several advantages," said Dr. Luigi Flagiello ...

Many employers are facing challenges in incorporating high-cost GLP-1 medications, such as Mounjaro, Ozempic, Rybelsus, Trulicity, and Wegovy, into their group health plans, as they must balance ...

Findings show benefits for patient survival. HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant ...

He also has mild, untreated sleep apnea. He would like to try one of the GLP-1 drugs to lose some weight, but I am concerned about possible pancreatitis due to his alcohol consumption.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were initially developed to regulate blood glucose levels in patients with type 2 diabetes mellitus (T2DM). However, their therapeutic effects ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.